地塞米松玻璃体内植入疗法治疗视网膜静脉阻塞性黄斑水肿及在临床实践中转换为雷珠单抗治疗

Dexamethasone Intravitreal Implant Therapy for Retinal Vein Occlusion Macular Oedema and Conversion to Ranibizumab in Clinical Practice.

作者信息

Balal Shafi, Than Jonathan, Tekriwal Sharmila, Lobo Aires

机构信息

Moorfields Eye Hospital, Bedford, UK.

出版信息

Ophthalmologica. 2018;239(1):36-44. doi: 10.1159/000479893. Epub 2017 Sep 27.

DOI:10.1159/000479893

PMID:28950262

Abstract

PURPOSE

Evaluation of outcomes in retinal vein occlusions (RVOs) for: (1) multiple repeat dexamethasone (DEX) injections and (2) conversion from DEX to ranibizumab.

METHODS

We conducted a retrospective study evaluating outcomes of multiple DEX injections and those requiring conversion to ranibizumab at Moorfields Eye Hospital, Bedford, UK. All patients had undergone a complete ophthalmic work-up.

RESULTS

Patients (n = 129) had a mean follow-up of 19.9 months. The mean improvement in central retinal thickness was 312 μm after final DEX (p = <0.0001). Mean peak best corrected visual acuity (BCVA) after final DEX was an improvement of 16 ETDRS letters (p < 0.0001). Forty-nine patients were converted and received a mean of 9.37 ranibizumab injections with a mean improvement in BCVA of 15 ETDRS letters (p < 0.0001) compared with final DEX.

CONCLUSIONS

This study supports the use of ranibizumab in eyes previously treated with DEX and provides long-term efficacy and safety data for multiple DEX injection.

摘要

目的

评估视网膜静脉阻塞（RVO）患者的治疗结果，包括：（1）多次重复注射地塞米松（DEX）以及（2）从DEX转换为雷珠单抗治疗的情况。

方法

我们进行了一项回顾性研究，评估了在英国贝德福德的摩尔菲尔德眼科医院接受多次DEX注射以及需要转换为雷珠单抗治疗的患者的治疗结果。所有患者均接受了全面的眼科检查。

结果

患者（n = 129）的平均随访时间为19.9个月。末次DEX注射后，视网膜中央厚度平均改善了312μm（p = <0.0001）。末次DEX注射后的平均最佳矫正视力（BCVA）峰值提高了16个ETDRS字母（p < 0.0001）。49例患者转换治疗，平均接受了9.37次雷珠单抗注射，与末次DEX注射相比，BCVA平均提高了15个ETDRS字母（p < 0.0001）。